RVPH - REVIVA ALERT: Bragar Eagel & Squire P.C. is Investigating Reviva Pharmaceuticals Holdings Inc. on Behalf of Reviva Stockholders and Encourages Investors to Contact the Firm | Benzinga
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ:RVPH) on behalf of Reviva stockholders. Our investigation concerns whether Reviva has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On April 15, 2024, Revival disclosed in a filing with the U.S. Securities and Exchange Commission that "[o]n April 12, 2024, the Audit Committee . . . of the Board of Directors . . . concluded that the Company's previously issued financial statements for the fiscal year ended December 31, 2022 included in its Annual Report on Form 10-K, the interim financial statements for the quarterly period ended September 30, 2022 included ...